Buy Pyrilutamide, or KX-826 is a potential first-in-class topical androgen receptor antagonist being developed by Kintor Pharma. It’s in phase II clinical trials for androgenic alopecia and acne vulgaris.
This drug is different from current treatments for AGA like minoxidil and finasteride due to its low side effects. This topical medication prevents androgens from binding to hair follicles, preventing miniaturization and resulting in more hair growth.
Pyrilutamide (development code KX-826) is a potential first-in-class topical androgen receptor antagonist for hair loss and acne. It has completed phase-2 clinical trials and is currently undergoing the phase-3 trial.
The drug inhibits DHT and testosterone from binding to the androgen receptor, thus stopping the androgen signaling pathway and reducing androgen levels. It has a similar mechanism of action as Ru58841, another popular anti-androgen.
Our PyriPure product is a pure solution of Buy Pyrilutamide in an ethanol and propylene glycol vehicle, which has been confirmed by a 3rd party lab to be >99% pure. The bottle also comes with a calibrated dropper for easy usage. All orders are shipped with this pipette. The solution maintains potency for a year upon mixing and can be kept in a cool dark place. The bottle holds 1ml. ***Please note that this is for laboratory developmental research USE ONLY, not for human consumption.
Pyrilutamide is an anti-androgen that works by blocking testosterone and DHT from binding to the hair follicle. It is a topical and has no systemic side effects. It’s similar to finasteride and RU58841, but has a different mechanism of action.
It has been shown to be well-tolerated with the most common adverse event being contact dermatitis. It is delivered in an optimised solution of 85% Ethanol to 15% PG for maximum effectiveness with no skin irritation.
Kintor Pharmaceuticals has just completed the enrollment of 120 patients in their Phase II clinical trials of KX-826, aka Pyrilutamide, for androgenetic alopecia. They also have a new compound called GT20029, an AR-PROTAC, that is currently in Phase 1 clinical trials. It’s expected to be in a tincture form and is targeted for use in both men and women. Both compounds target DHT, which is thought to be the primary cause of androgenetic alopecia in most people. The results of these trials should be available in 2023.
Pyrilutamide is a potent androgen receptor antagonist. It blocks both testosterone and DHT from binding to the androgen receptor in the hair follicles. This results in a significant reduction of androgen production and stops hair loss. It is a much more gentle approach than finasteride and a possible alternative to topical treatments like DHT Blockers.
It has been shown to be safe and effective in a phase 2 clinical trial in China for androgenetic alopecia, a randomized, double-blind, placebo-controlled study with multiple ascending doses. Buy Pyrilutamide in Europe also showed excellent pharmacokinetics.
It is expected to enter a phase 3 clinical trial in the US next year (2021). If successful, this drug could potentially be the first topical androgen receptor antagonist approved for male pattern baldness. It is very similar in structure to RU58841 which was recently approved by the FDA for androgenetic alopecia. Pyrilutamide is also undergoing phase 2 trials for prostate cancer and other male-specific conditions.
Buy Pyrilutamide is a new antiandrogen drug that could be the biggest development in hair loss treatments since finasteride. This high-potency topical androgen receptor antagonist was developed by Kintor Pharmaceutical Limited as a potential treatment for androgenic alopecia. It is the highest potency topical AR antagonist available, and it works by blocking testosterone and DHT from binding to the androgen receptor in the hair follicle and damaging it.
It is being researched in phase II clinical trials for androgenic alopecia by Kintor Pharmaceutical Limited. These trials are randomized, double-blind and placebo-controlled to ensure that the compound meets efficacy and safety standards set by the FDA.
Pyrilutamide is toxic and should only be handled by individuals trained and experienced in handling potent active pharmaceutical ingredients. It should be stored in a cool, dark area to prevent degradation and crystallization. Pyrilutamide powder will keep stable for several years after mixing in an ethanol and propylene glycol solution.